EOLS
Bearish signal
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Financial indicators Unavailable or mixed. Current ratio 1.90 · operating margin -13% — readings disagree
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. No stored price series
VENTE TOTALE: 105 108 titres (~950 018,66 $ US)
- Insiders
- MOATAZEDI DAVID
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$950,019
Avg sell (VWAP, 90d window) $9.04 vs last close —
- Last activity
- 2026-09-02
- Last synced
-
2026-09-08 09:54:45
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-02 | MOATAZEDI DAVID | Sell | 105,108 | $9.04 | $950,019 | Form 4 |
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Market snapshot
Signal
Bearish signalScored 2026-09-08
EOLS presents a deeply concerning financial profile with persistent losses, negative ROIC, and a debt-to-capital ratio exceeding 1.0, making the fundamental foundation extremely fragile.
The first sentence of the analysis written for EOLS on 2026-09-08 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 64.9% | 68.5% | 69.5% | 60.4% | 56.3% | |
| Ebit Margin | -10.5% | -11.7% | -23.6% | -38.7% | -45.5% | |
| Ebitda Margin | -7.6% | -9.4% | -20.7% | -36.2% | -39.2% | |
| Operating Profit Margin | -12.7% | -12.9% | -24.4% | -44.0% | -44.6% | |
| Pretax Profit Margin | -17.1% | -18.7% | -30.4% | -50.0% | -46.9% | |
| Continuous Operations Profit Margin | -17.4% | -18.9% | -30.5% | -50.1% | -47.0% | |
| Net Profit Margin | -17.4% | -18.9% | -30.5% | -50.1% | -47.0% | |
| Bottom Line Profit Margin | -17.4% | -18.9% | -30.5% | -50.1% | -47.0% | |
| Current Ratio | 1.898 | 2.404 | 2.328 | 2.167 | 3.101 | |
| Quick Ratio | 1.540 | 2.211 | 2.100 | 1.762 | 3.070 | |
| Solvency Ratio | -0.172 | -0.196 | -0.266 | -0.443 | -0.231 | |
| Cash Ratio | 0.715 | 1.381 | 1.301 | 1.159 | 2.536 | |
| Price To Earnings Ratio | -8.312 | -13.630 | -9.750 | -5.647 | -6.926 | |
| Price To Earnings Growth Ratio | 6.733 | 0.545 | 0.519 | -0.136 | 0.086 | |
| Forward Price To Earnings Growth Ratio | 6.733 | 0.545 | 0.519 | -0.136 | 0.086 | |
| Price To Earnings Diluted Ratio | -8.312 | -13.630 | -9.750 | -5.647 | -6.926 | |
| Price To Earnings Diluted Growth Ratio | 6.733 | 0.545 | 0.519 | -0.136 | 0.086 | |
| Price To Book Ratio | -18.554 | 123.989 | -28.970 | 22.761 | 3.957 | |
| Price To Sales Ratio | 1.443 | 2.571 | 2.966 | 2.833 | 3.251 | |
| Price To Free Cash Flow Ratio | -8.453 | -35.163 | -16.819 | -4.793 | -9.431 | |
| Price To Operating Cash Flow Ratio | -10.144 | -38.039 | -17.624 | -4.959 | -9.705 | |
| Debt To Assets Ratio | 0.686 | 0.559 | 0.670 | 0.418 | 0.290 | |
| Debt To Equity Ratio | -6.708 | 23.538 | -6.117 | 4.023 | 0.913 | |
| Debt To Capital Ratio | 1.175 | 0.959 | 1.195 | 0.801 | 0.477 | |
| Long Term Debt To Capital Ratio | 1.188 | 0.957 | 1.208 | 0.795 | 0.465 | |
| Financial Leverage Ratio | -9.775 | 42.117 | -9.135 | 9.621 | 3.145 | |
| Working Capital Turnover Ratio | 3.810 | 3.492 | 3.413 | 1.694 | 2.910 | |
| Operating Cash Flow Ratio | -0.561 | -0.286 | -0.704 | -1.826 | -0.579 | |
| Operating Cash Flow Sales Ratio | -0.142 | -0.068 | -0.168 | -0.571 | -0.335 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.200 | 1.082 | 1.048 | 1.035 | 1.029 | |
| Debt Service Coverage Ratio | -1.178 | -1.370 | -3.035 | -5.930 | -28.009 | |
| Interest Coverage Ratio | -1.909 | -1.837 | -3.559 | -7.181 | -31.809 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -0.273 | -0.138 | -0.269 | -1.141 | -0.447 | |
| Capital Expenditure Coverage Ratio | -5.001 | -12.228 | -20.902 | -28.891 | -34.421 | |
| Dividend Paid And Capex Coverage Ratio | -5.001 | -12.228 | -20.902 | -28.891 | -34.421 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -23.522 | -29.107 | -15.859 | -8.199 | -6.465 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 64.9% | ▼-3.6% | ▲0.9% |
| Ebit Margin | -10.5% | ▲1.1% | ▲15.5% |
| Ebitda Margin | -7.6% | ▲1.8% | ▲15.0% |
| Operating Profit Margin | -12.7% | ▲0.3% | ▲15.0% |
| Pretax Profit Margin | -17.2% | ▲1.5% | ▲15.5% |
| Continuous Operations Profit Margin | -17.4% | ▲1.6% | ▲15.4% |
| Net Profit Margin | -17.4% | ▲1.6% | ▲15.4% |
| Bottom Line Profit Margin | -17.4% | ▲1.6% | ▲15.4% |
| Current Ratio | 1.898 | ▼-0.506 | ▼-0.482 |
| Quick Ratio | 1.540 | ▼-0.671 | ▼-0.597 |
| Solvency Ratio | -0.172 | ▲0.023 | ▲0.089 |
| Cash Ratio | 0.715 | ▼-0.666 | ▼-0.704 |
| Price To Earnings Ratio | -8.312 | ▲5.317 | ▲0.540 |
| Price To Earnings Growth Ratio | 6.733 | ▲6.188 | ▲5.184 |
| Forward Price To Earnings Growth Ratio | 6.733 | ▲6.188 | ▲5.184 |
| Price To Earnings Diluted Ratio | -8.312 | ▲5.317 | ▲0.540 |
| Price To Earnings Diluted Growth Ratio | 6.733 | ▲6.188 | ▲5.184 |
| Price To Book Ratio | -18.554 | ▼-142.543 | ▼-39.191 |
| Price To Sales Ratio | 1.443 | ▼-1.129 | ▼-1.170 |
| Price To Free Cash Flow Ratio | -8.453 | ▲26.710 | ▲6.479 |
| Price To Operating Cash Flow Ratio | -10.144 | ▲27.896 | ▲5.950 |
| Debt To Assets Ratio | 0.686 | ▲0.127 | ▲0.162 |
| Debt To Equity Ratio | -6.708 | ▼-30.246 | ▼-9.838 |
| Debt To Capital Ratio | 1.175 | ▲0.216 | ▲0.254 |
| Long Term Debt To Capital Ratio | 1.188 | ▲0.231 | ▲0.265 |
| Financial Leverage Ratio | -9.775 | ▼-51.892 | ▼-16.970 |
| Working Capital Turnover Ratio | 3.810 | ▲0.318 | ▲0.746 |
| Operating Cash Flow Ratio | -0.561 | ▼-0.275 | ▲0.230 |
| Operating Cash Flow Sales Ratio | -0.142 | ▼-0.075 | ▲0.115 |
| Free Cash Flow Operating Cash Flow Ratio | 1.200 | ▲0.118 | ▲0.121 |
| Debt Service Coverage Ratio | -1.178 | ▲0.192 | ▲6.726 |
| Interest Coverage Ratio | -1.909 | ▼-0.072 | ▲7.350 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | -0.273 | ▼-0.134 | ▲0.181 |
| Capital Expenditure Coverage Ratio | -5.001 | ▲7.227 | ▲15.288 |
| Dividend Paid And Capex Coverage Ratio | -5.001 | ▲7.227 | ▲15.288 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -23.522 | ▲5.584 | ▼-6.892 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $428.7M | $684.7M | $599.4M | $421.1M | $324.0M | |
| Enterprise value | $529.9M | $727.7M | $663.1M | $441.6M | $252.5M | |
| EV / Sales | 1.78x | 2.73x | 3.28x | 2.97x | 2.53x | |
| EV / Op. cash flow | -12.54x | -40.43x | -19.50x | -5.20x | -7.56x | |
| EV / Free cash flow | -10.45x | -37.37x | -18.61x | -5.03x | -7.35x | |
| EV / EBITDA | -23.52x | -29.11x | -15.86x | -8.20x | -6.46x | |
| Net debt / EBITDA | -4.49x | -1.72x | -1.52x | -0.38x | 1.83x | |
| Current ratio | 1.90x | 2.40x | 2.33x | 2.17x | 3.10x | |
| Income quality | 0.82x | 0.36x | 0.55x | 1.14x | 0.71x | |
| Graham net-net | -$2 | -$2 | -$2 | -$1 | -$0 | |
| Tax burden | 101.3% | 101.3% | 100.3% | 100.1% | 100.1% | |
| Interest burden | 163.0% | 160.4% | 129.0% | 129.1% | 103.1% | |
| Working capital | $67.6M | $88.4M | $64.1M | $54.3M | $121.1M | |
| Invested capital | $149.4M | $168.8M | $140.3M | $128.7M | $197.1M | |
| Return on assets | -22.9% | -21.7% | -32.6% | -41.8% | -18.2% | |
| Operating ROA | -16.4% | -16.3% | -26.8% | -30.0% | -19.0% | |
| Return on tangible assets | -33.0% | -31.0% | -51.1% | -68.8% | -25.2% | |
| Return on equity | 223.5% | -913.1% | 298.2% | -402.2% | -57.2% | |
| Return on invested capital | -24.6% | -20.1% | -34.7% | -49.2% | -22.1% | |
| Return on capital employed | -25.0% | -20.3% | -35.0% | -49.7% | -22.2% | |
| Earnings yield | -12.0% | -7.4% | -10.3% | -17.7% | -14.4% | |
| Free cash flow yield | -11.8% | -2.8% | -5.9% | -20.9% | -10.6% | |
| Capex / Op. cash flow | -20.0% | -8.2% | -4.8% | -3.5% | -2.9% | |
| Capex / Depreciation | 96.7% | 24.5% | 27.7% | 65.4% | 15.4% | |
| Capex / Sales | 2.8% | 0.6% | 0.8% | 2.0% | 1.0% | |
| SG&A / Sales | 74.3% | 74.4% | 81.6% | 95.4% | 112.4% | |
| R&D / Sales | 3.2% | 3.4% | 7.6% | 4.5% | 2.1% | |
| Stock comp / Sales | 7.0% | 8.4% | 8.1% | 7.3% | 9.6% | |
| Intangibles / Total assets | 30.7% | 30.1% | 36.1% | 39.2% | 27.9% | |
| Days sales outstanding | 67d | 65d | 55d | 55d | 54d | |
| Days payables outstanding | 82d | 40d | 25d | 55d | 51d | |
| Operating cycle | 161d | 118d | 120d | 172d | 68d | |
| Cash conversion cycle | 80d | 78d | 95d | 117d | 17d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▼-37.4%EV / Sales ▼-34.8%EV / EBITDA ▲+19.2%EV / Op. cash flow ▲+27.892Earnings yield ▼-0.047
Profitability
Return on equity ▲+11.366Return on assets ▼-0.012Return on invested capital ▼-0.045Return on capital employed ▼-0.047Operating ROA ▼-0.001Income quality ▲+0.461Tax burden -0.000
Efficiency
Days sales outstanding ▲+1.819Days payables outstanding ▲+41.513Operating cycle ▲+43.226Cash conversion cycle ▲+1.713Capex / Sales ▲+0.023R&D / Sales ▼-0.002
Balance-sheet strength
Current ratio ▼-0.506Net debt / EBITDA ▼-2.770Working capital ▼-20770000.000Invested capital ▼-19387000.000Intangibles / Total assets ▲+0.006
Change over 5 years
Valuation
Market cap ▲+32.3%EV / Sales ▼-29.6%EV / EBITDA ▼-263.8%EV / Op. cash flow ▼-4.974Earnings yield ▲+0.024
Profitability
Return on equity ▲+2.807Return on assets ▼-0.047Return on invested capital ▼-0.025Return on capital employed ▼-0.028Operating ROA ▲+0.026Income quality ▲+0.105Tax burden ▲+0.012
Efficiency
Days sales outstanding ▲+13.507Days payables outstanding ▲+30.591Operating cycle ▲+92.988Cash conversion cycle ▲+62.397Capex / Sales ▲+0.019R&D / Sales ▲+0.012
Balance-sheet strength
Current ratio ▼-1.203Net debt / EBITDA ▼-6.322Working capital ▼-53524000.000Invested capital ▼-47698000.000Intangibles / Total assets ▲+0.028
Employee count
Peer market caps
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent news
- 2026-09-02 BlackRock Inc. Makes New Investment in Evolus, Inc. $EOLS BlackRock Inc. acquired a new stake in shares of Evolus, Inc. (NASDAQ: EOLS) during the second quarter, according to its most recent disclosure with the SEC. The fund acquired 4,840,828 shares of the company''s stock, valued at approximately $33,595,000. BlackRock Inc. owned approximately 7.35% of Evolus as of its most recent SEC filing.
- 2026-09-01 A Wave of Weight-Loss Drugs Is Quietly Creating a Multi-Billion-Dollar Opportunity That Aesthetic Medicine Is Racing to Capture A Wave of Weight-Loss Drugs Is Quietly Creating a Multi-Billion-Dollar Opportunity That Aesthetic Medicine Is Racing to Capture P
- 2026-08-27 Wall Street Analysts Think Evolus (EOLS) Could Surge 77.68%: Read This Before Placing a Bet The mean of analysts'' price targets for Evolus (EOLS) points to a 77.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- 2026-08-25 Evolus (NASDAQ:EOLS) Reaches New 52-Week High – Time to Buy? Evolus, Inc. (NASDAQ: EOLS - Get Free Report)''s stock price reached a new 52-week high during mid-day trading on Tuesday. The stock traded as high as $8.82 and last traded at $8.78, with a volume of 1320192 shares. The stock had previously closed at $8.39. Wall Street Analysts Forecast Growth EOLS has been the subject
- 2026-08-12 Assenagon Asset Management S.A. Grows Stock Holdings in Evolus, Inc. $EOLS Assenagon Asset Management S.A. lifted its holdings in Evolus, Inc. (NASDAQ: EOLS) by 51.8% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 908,180 shares of the company''s stock after acquiring an additional 310,035 shares during the period. Assenagon Asset
- 2026-08-11 Wall Street Analysts Believe Evolus (EOLS) Could Rally 106.08%: Here''s is How to Trade The average of price targets set by Wall Street analysts indicates a potential upside of 106.1% in Evolus (EOLS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- 2026-08-11 Evolus: The Injectable Platform Is Becoming The Real Moat Evolus is evolving into a multi-product aesthetics platform, leveraging its distribution network and loyalty ecosystem to drive operating leverage and recurring revenue. Q2 2026 results showed 21% revenue growth, positive adjusted EBITDA, and raised guidance, with management projecting 2028 revenue of $450M–$500M and EBITDA margins of 13–15%. Evolus trades at a forward EV/Sales of 1.86, a 50% discount to sector median, but requires margin expansion to justify valuation as it transitions from single-product to platform economics.
- 2026-08-06 Evolus, Inc. (EOLS) Q2 2026 Earnings Call Transcript Evolus, Inc. (EOLS) Q2 2026 Earnings Call Transcript
- 2026-08-05 Evolus, Inc. (EOLS) Reports Break-Even Earnings for Q2 Evolus, Inc. (EOLS) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to a loss of $0.24 per share a year ago.
- 2026-08-05 Evolus Q2 Earnings Call Highlights Evolus NASDAQ: EOLS reported second-quarter revenue growth of 21% and raised the lower end of its full-year 2026 revenue outlook, citing market-share gains in neurotoxins and hyaluronic acid injectable gels, continued customer adoption of its portfolio and expanding international operations.